株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

変形性関節症疼痛:パイプライン製品の分析

Osteoarthritis Pain - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232825
出版日 ページ情報 英文 212 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
変形性関節症疼痛:パイプライン製品の分析 Osteoarthritis Pain - Pipeline Review, H2 2016
出版日: 2016年10月29日 ページ情報: 英文 212 Pages
概要

変形性関節症疼痛は、軟骨の損傷に伴い発症する骨関節炎を伴う最も一般的な症状です。

当レポートでは、変形性関節症疼痛の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

変形性関節症疼痛の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

変形性関節症疼痛:企業で開発中の治療薬

変形性関節症疼痛:大学/機関で研究中の治療薬

変形性関節症疼痛:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

変形性関節症疼痛:企業で開発中の製品

変形性関節症疼痛:大学/機関で研究中の製品

変形性関節症疼痛の治療薬開発に従事している企業

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • Afferent Pharmaceuticals, Inc.
  • Akron Molecules AG
  • Allergan Plc
  • Amgen Inc.
  • Ampio Pharmaceuticals, Inc.
  • AnaMar AB
  • Antibe Therapeutics, Inc.
  • AskAt Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bone Medical Limited
  • Centrexion Corporation
  • Convergence Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Elite Pharmaceuticals, Inc.
  • Flexion Therapeutics, Inc.
  • Grunenthal GmbH
  • Iroko Pharmaceuticals, LLC
  • Nektar Therapeutics
  • Nuvo Research Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • Pozen, Inc.
  • Purdue Pharma L.P.
  • Regeneron Pharmaceuticals, Inc.
  • Rottapharm SpA

変形性関節症疼痛:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

変形性関節症疼痛:最近のパイプライン動向

変形性関節症疼痛:休止中のプロジェクト

変形性関節症疼痛:開発が中止された製品

変形性関節症疼痛:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8600IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2016, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 19, 6, 1, 17, 5 and 1 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Osteoarthritis Pain.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoarthritis Pain Overview
  • Therapeutics Development
  • Osteoarthritis Pain - Therapeutics under Development by Companies
  • Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes
  • Osteoarthritis Pain - Pipeline Products Glance
  • Osteoarthritis Pain - Products under Development by Companies
  • Osteoarthritis Pain - Products under Investigation by Universities/Institutes
  • Osteoarthritis Pain - Companies Involved in Therapeutics Development
  • Osteoarthritis Pain - Therapeutics Assessment
  • Drug Profiles
  • Osteoarthritis Pain - Dormant Projects
  • Osteoarthritis Pain - Discontinued Products
  • Osteoarthritis Pain - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Osteoarthritis Pain, H2 2016
  • Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Osteoarthritis Pain - Pipeline by AbbVie Inc, H2 2016
  • Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Akron Molecules AG, H2 2016
  • Osteoarthritis Pain - Pipeline by Allergan Plc, H2 2016
  • Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by AskAt Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H2 2016
  • Osteoarthritis Pain - Pipeline by Biogen Inc, H2 2016
  • Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Osteoarthritis Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
  • Osteoarthritis Pain - Pipeline by Chromocell Corporation, H2 2016
  • Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H2 2016
  • Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Genzyme Corporation, H2 2016
  • Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Osteoarthritis Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016
  • Osteoarthritis Pain - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Osteoarthritis Pain - Pipeline by MedImmune, LLC, H2 2016
  • Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Pfizer Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H2 2016
  • Osteoarthritis Pain - Pipeline by pSivida Corp., H2 2016
  • Osteoarthritis Pain - Pipeline by Purdue Pharma LP, H2 2016
  • Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Osteoarthritis Pain - Pipeline by Symic Biomedical, Inc., H2 2016
  • Osteoarthritis Pain - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
  • Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Osteoarthritis Pain - Dormant Projects, H2 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..1), H2 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..2), H2 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..3), H2 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..4), H2 2016
  • Osteoarthritis Pain - Discontinued Products, H2 2016
  • Osteoarthritis Pain - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Osteoarthritis Pain, H2 2016
  • Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top